TOPLINE:
A meta-analysis of randomized controlled trials involving over 59,000 patients with diabetes or obesity showed no statistically significant difference in the risk for suicide between those treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and placebo.
METHODOLOGY:
- Initial reports of increased suicidality in GLP-1 RA users compared with the general population raised concerns about the risk for this rare but serious adverse event, given the rising popularity of these medications.
- Researchers conducted a systematic review and meta-analysis of randomized, placebo-controlled trials lasting 6 or more months to assess the risk for suicides, suicide attempts, suicidal thoughts, and self-harm in patients treated with GLP-1 RAs for diabetes or obesity.
- Data collection involved systematic searches of…